Trials / Recruiting
RecruitingNCT06246071
A Study of TYK-00540 in Adult Patients With Solid Tumors
A Phase Ia/Ib, Multicenter, Open-label Study of TYK-00540, Administered Orally in Adult Patients With Locally Advanced/Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 156 (estimated)
- Sponsor
- TYK Medicines, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate the safety and tolerability of TYK-00540, with dose-escalation stage and dose-expansion stage.
Detailed description
To evaluate dose limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) in subjects with locally advanced or metastatic solid tumors. To investigate the pharmacokinetic profile of TYK-00540 and its metabolites after single then multiple doses of TYK-00540 administered orally once daily. To assess preliminary effectiveness.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TYK-00540 | TYK-00540 PO, BID |
Timeline
- Start date
- 2024-01-02
- Primary completion
- 2026-12-05
- Completion
- 2026-12-05
- First posted
- 2024-02-07
- Last updated
- 2024-02-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06246071. Inclusion in this directory is not an endorsement.